The MarketBeat consensus price target on the stock sits near $1,218, implying upside of just over 20%
For GLP-1 drugs specifically, the landscape has shifted dramatically
GLP-1 medications are powerful tools, but they are not passive treatments, and patients who combine them with proper nutrition, strength training and medical oversight are more likely to achieve healthier and more sustainable outcomes, she said
Whether you're cutting, recomposing, or just taking back controlGLP-1X was built to shift your internal state from reactive to resilient
The 2025 Prohibited List and WADAs explanatory note on the modifications can be found here
Providers are independent professionals who make their own prescribing decisions based on each patient's individual health profile